ReviewJournal of cellular and molecular medicine2012
Cerebral correlates of psychotic syndromes in neurodegenerative diseases.
Review in Journal of cellular and molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study.BMC neurology · 2025Trial
- Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.The journal of prevention of Alzheimer's disease · 2019Trial
- The Modified Functional Status Questionnaire for Assessing Patients with Parkinson's Disease Psychosis Treated with Pimavanserin: A Post Hoc Analysis.Neurology and therapy · 2025Article
- Article
- The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson's disease psychosis: a 16-week, single-arm, open-label study.Therapeutic advances in neurological disorders · 2024Article
- White matter hyperintensities and smaller cortical thickness are associated with neuropsychiatric symptoms in neurodegenerative and cerebrovascular diseases.Alzheimer's research & therapy · 2023Article
- The Association of Antipsychotic Postponement With 5-Year Outcomes of Adolescent First-Episode Psychosis.Schizophrenia bulletin open · 2023Article
- Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel.Neurology and therapy · 2022Article
- Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis.Frontiers in neurology · 2022Article
- Relevance of 5-HTCNS drugs · 2021Review
- Correlation of Frontal Atrophy and CSF Tau Levels With Neuropsychiatric Symptoms in Patients With Cognitive Impairment: A Memory Clinic Experience.Frontiers in aging neuroscience · 2021Article
- Transgenerational Interaction of Alzheimer's Disease with Schizophrenia through Amyloid Evolvability.Journal of Alzheimer's disease : JAD · 2019Review
- Pimavanserin: Potential Treatment For Dementia-Related Psychosis.The journal of prevention of Alzheimer's disease · 2018Review
- Clinicopathological Study of Patients With C9ORF72-Associated Frontotemporal Dementia Presenting With Delusions.Journal of geriatric psychiatry and neurology · 2015Article
- The Spectrum of Psychiatric Pathology in a Patient with Genetically Verified Huntington's Disease.Case reports in psychiatry · 2015Article
- Argyrophilic grain disease as a neurodegenerative substrate in late-onset schizophrenia and delusional disorders.European archives of psychiatry and clinical neuroscience · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychosis has been recognized as a common feature in neurodegenerative diseases and a core feature of dementia that worsens most clinical courses. It includes hallucinations, delusions including paranoia, aggressive behaviour, apathy and other psychotic phenomena that occur in a wide range of degenerative disorders including Alzheimer's disease, synucleinopathies (Parkinson's disease, dementia with Lewy bodies), Huntington's disease, frontotemporal degenerations, motoneuron and prion diseases. Many of these psychiatric manifestations may be early expressions of cognitive impairment, but often there is a dissociation between psychotic/behavioural symptoms and the rather linear decline in cognitive function, suggesting independent pathophysiological mechanisms. Strictly neuropathological explanations are likely to be insufficient to explain them, and a large group of heterogeneous factors (environmental, neurochemical changes, genetic factors, etc.) may influence their pathogenesis. Clinico-pathological evaluation of behavioural and psychotic symptoms (PS) in the setting of neurodegenerative and dementing disorders presents a significant challenge for modern neurosciences. Recognition and understanding of these manifestations may lead to the development of more effective preventive and therapeutic options that can serve to delay long-term progression of these devastating disorders and improve the patients' quality of life. A better understanding of the pathophysiology and distinctive pathological features underlying the development of PS in neurodegenerative diseases may provide important insights into psychotic processes in general.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.